Theralase Technologies Inc. (TLTFF)
OTCMKTS · Delayed Price · Currency is USD
0.2200
-0.0100 (-4.35%)
Feb 12, 2026, 3:11 PM EST
Theralase Technologies Revenue
Theralase Technologies had revenue of 279.64K CAD in the quarter ending September 30, 2025, a decrease of -19.32%. This brings the company's revenue in the last twelve months to 1.00M, up 1.46% year-over-year. In the year 2024, Theralase Technologies had annual revenue of 1.03M, down -3.45%.
Revenue (ttm)
1.00M CAD
Revenue Growth
+1.46%
P/S Ratio
81.40
Revenue / Employee
50.05K CAD
Employees
20
Market Cap
58.50M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.03M | -36.88K | -3.45% |
| Dec 31, 2023 | 1.07M | -68.26K | -6.00% |
| Dec 31, 2022 | 1.14M | 357.93K | 45.85% |
| Dec 31, 2021 | 780.64K | -148.48K | -15.98% |
| Dec 31, 2020 | 929.12K | -34.93K | -3.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
Theralase Technologies News
- 2 days ago - Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting - Newsfile Corp
- 8 days ago - Theralase(R) Provides Update on Bladder Cancer Clinical Study - Newsfile Corp
- 4 weeks ago - Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer - Newsfile Corp
- 4 weeks ago - Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer - Business Wire
- 7 weeks ago - Theralase(R) Closes $1.3 M Non-Brokered Private Placement - Newsfile Corp
- 2 months ago - Theralase Technologies (TLTFF) Launches C$2M Private Placement - GuruFocus
- 2 months ago - Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing - Newsfile Corp
- 2 months ago - Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study - Newsfile Corp